Cargando…

Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC), one of the most fatal malignancies in the world, is usually diagnosed in advanced stages due to late symptom manifestation with very limited therapeutic options, which leads to ineffective intervention and dismal prognosis. For a decade, tyrosine kinase inhibitors (TK...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xing, Rui, Gao, Jinping, Cui, Qi, Wang, Qian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8660685/ https://www.ncbi.nlm.nih.gov/pubmed/34899747 http://dx.doi.org/10.3389/fimmu.2021.783236

Ejemplares similares

Immunotherapy of hepatocellular carcinoma: recent progress and new strategy
por: Li, Jiarui, et al.
Publicado: (2023)

Bibliometric study of immunotherapy for hepatocellular carcinoma
por: Li, Zhiyi, et al.
Publicado: (2023)

DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma
por: Chen, Yunfei, et al.
Publicado: (2021)

Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies
por: Giraud, Julie, et al.
Publicado: (2021)

HDAC inhibitors enhance the anti-tumor effect of immunotherapies in hepatocellular carcinoma
por: Shen, Chen, et al.
Publicado: (2023)

Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma: A network meta-analysis and cost-effectiveness analysis
por: Liu, Kun, et al.
Publicado: (2023)

Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects
por: Liu, Zhuoyan, et al.
Publicado: (2021)

Estrogen-related genes influence immune cell infiltration and immunotherapy response in Hepatocellular Carcinoma
por: Gao, Biao, et al.
Publicado: (2023)

The role of histone methylase and demethylase in antitumor immunity: A new direction for immunotherapy
por: Zhang, Yuanling, et al.
Publicado: (2023)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: Where We Are and Where to Go
por: Wang, Kunpeng, et al.
Publicado: (2021)

Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study
por: Shen, Jianming, et al.
Publicado: (2022)

Current insights into the hepatic microenvironment and advances in immunotherapy for hepatocellular carcinoma
por: Zhao, Ming, et al.
Publicado: (2023)

Bromo‐ and extraterminal domain protein inhibition improves immunotherapy efficacy in hepatocellular carcinoma
por: Liu, Chen, et al.
Publicado: (2020)

Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond
por: Lee, Yun Hua, et al.
Publicado: (2020)

Aging-related features predict prognosis and immunotherapy efficacy in hepatocellular carcinoma
por: Hong, Ting, et al.
Publicado: (2022)

Combinatory local ablation and immunotherapies for hepatocellular carcinoma: Rationale, efficacy, and perspective
por: Chen, Shuling, et al.
Publicado: (2022)

Characterization of immune features and immunotherapy response in subtypes of hepatocellular carcinoma based on mitophagy
por: Wang, Yanan, et al.
Publicado: (2022)

Immunological and Translational Aspects of NK Cell-Based Antitumor Immunotherapies
por: Shevtsov, Maxim, et al.
Publicado: (2016)

Strategies to Improve the Antitumor Effect of γδ T Cell Immunotherapy for Clinical Application
por: Miyashita, Masatsugu, et al.
Publicado: (2021)

Prognostic signatures of sphingolipids: Understanding the immune landscape and predictive role in immunotherapy response and outcomes of hepatocellular carcinoma
por: Zhang, Xin, et al.
Publicado: (2023)

CD93 overexpresses in liver hepatocellular carcinoma and represents a potential immunotherapy target
por: Jiang, Qianwei, et al.
Publicado: (2023)

Deciphering a mitochondria-related signature to supervise prognosis and immunotherapy in hepatocellular carcinoma
por: Shi, Yanlong, et al.
Publicado: (2022)

Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?
por: Jiang, Jingyu, et al.
Publicado: (2023)

Strategies to Improve the Efficacy of Dendritic Cell-Based Immunotherapy for Melanoma
por: Hargadon, Kristian M.
Publicado: (2017)

Necroptosis throws novel insights on patient classification and treatment strategies for hepatocellular carcinoma
por: Hu, Bowen, et al.
Publicado: (2022)

Viral Status and Efficacy of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis
por: Ding, Ziniu, et al.
Publicado: (2021)

CTNNB1 Alternation Is a Potential Biomarker for Immunotherapy Prognosis in Patients With Hepatocellular Carcinoma
por: Chen, Lin, et al.
Publicado: (2021)

Characterizing hepatocellular carcinoma stem markers and their corresponding susceptibility to NK-cell based immunotherapy
por: Chiang, Jason, et al.
Publicado: (2023)

A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy
por: Satta, Alessandro, et al.
Publicado: (2019)

Portal vein tumour thrombosis radiotherapy improves the treatment outcomes of immunotherapy plus bevacizumab in hepatocellular carcinoma: a multicentre real-world analysis with propensity score matching
por: Tang, Cuiping, et al.
Publicado: (2023)

Prognostic stratification based on m(5)C regulators acts as a novel biomarker for immunotherapy in hepatocellular carcinoma
por: Liu, Ping, et al.
Publicado: (2022)

TCR T cells overexpressing c-Jun have better functionality with improved tumor infiltration and persistence in hepatocellular carcinoma
por: Hussein, Mohamed S., et al.
Publicado: (2023)

Innovative Strategies to Improve the Clinical Application of NK Cell-Based Immunotherapy
por: Tarannum, Mubin, et al.
Publicado: (2022)

Development of Immunotherapy Strategies Targeting Tumor Microenvironment Is Fiercely Ongoing
por: Bai, Rilan, et al.
Publicado: (2022)

Abrine, an IDO1 inhibitor, suppresses the immune escape and enhances the immunotherapy of anti-PD-1 antibody in hepatocellular carcinoma
por: Liang, Xiaowei, et al.
Publicado: (2023)

SRA inhibition improves antitumor potency of antigen-targeted chaperone vaccine
por: Qian, Jie, et al.
Publicado: (2023)

The Eltrombopag antitumor effect on hepatocellular carcinoma
por: KUROKAWA, TOMOHIRO, et al.
Publicado: (2015)

Antitumoral effect of Ocoxin in hepatocellular carcinoma
por: Díaz-Rodríguez, Elena, et al.
Publicado: (2017)

Beneficial Effect of Antibiotics and Microbial Metabolites on Expanded Vδ2Vγ9 T Cells in Hepatocellular Carcinoma Immunotherapy
por: Han, Jiajia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g0c7n4cjg6dn6ubdch4eps7gg6